Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

2.0K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.0K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

625
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
625
Peptic Ulcer01:27

Peptic Ulcer

20
Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the...
20
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

759
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
759
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.2K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.2K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.6K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How to Improve Patient Adherence During Helicobacter pylori Diagnosis and Treatment.

Helicobacter·2026
Same author

Helicobacter 30 Years On: A Message From the Editor, Emeritus.

Helicobacter·2026
Same author

The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions.

Gastroenterology·2026
Same author

40 years after the discovery of <i>Helicobacter Pylori</i>: Performing optimized "subtraction" for clinical eradication.

iMetaOmics·2026
Same author

Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population.

Helicobacter·2025
Same author

Elastic Cytomatrix Dynamics Influences Metabolic Rate and Tumor Microenvironment Formation.

Cancers·2025

Related Experiment Video

Updated: Mar 22, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

886

Helicobacter pylori therapy: a paradigm shift.

David Y Graham1, Maria Pina Dore1,2

  • 1a Department of Medicine , Michael E. DeBakey VA Medical Center and Baylor College of Medicine and Houston , Houston , TX , USA.

Expert Review of Anti-Infective Therapy
|April 15, 2016
PubMed
Summary
This summary is machine-generated.

High cure rates for Helicobacter pylori infections are achievable with appropriate antibiotic selection. Understanding antibiotic resistance prevalence is key to predicting and optimizing eradication therapy success.

Keywords:
Helicobacter pyloriamoxicillinbismuthclarithromycinlevofloxacinmetronidazoleproton pump inhibitortetracyclinetherapy

More Related Videos

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.6K
One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

10.2K

Related Experiment Videos

Last Updated: Mar 22, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

886
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.6K
One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

10.2K

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Helicobacter pylori (H. pylori) is a primary cause of gastroduodenal diseases, including gastric cancer.
  • Effective eradication therapies are crucial for managing H. pylori infections and preventing associated pathologies.

Purpose of the Study:

  • To summarize current H. pylori eradication therapies and their efficacy.
  • To provide a method for predicting treatment efficacy based on antibiotic resistance prevalence.
  • To offer guidance on selecting appropriate therapies and interpreting research data.

Main Methods:

  • Review and synthesis of existing data on H. pylori eradication regimens.
  • Development of a predictive model for treatment efficacy incorporating antibiotic resistance rates.
  • Formulation of recommendations for empiric therapy and susceptibility testing.

Main Results:

  • Several H. pylori treatment regimens achieve high cure rates (>90-95%) in populations with susceptible bacterial strains.
  • No single regimen has demonstrated superiority across all populations.
  • Antibiotic resistance prevalence significantly impacts treatment efficacy, necessitating susceptibility-based approaches.

Conclusions:

  • High H. pylori cure rates are reliably achievable when the infection is managed as a bacterial disease.
  • Susceptibility testing should be prioritized to guide H. pylori eradication therapy.
  • Accurate prediction of regimen efficacy requires knowledge of local antibiotic resistance patterns.